Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma

X
Trial Profile

Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camptothecin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Mar 2016 Results from this trial have been published in the Proceedings of the National Academy of Sciences (PNAS), according to a Cerulean Pharma media release.
    • 23 Mar 2016 Results published in a Cerulean media release.
    • 09 Nov 2015 Data was presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Cerulean Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top